{"id":"placebo-to-glipizide","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hypoglycemia"},{"rate":"2-3","effect":"Weight gain"},{"rate":"5-7","effect":"Dizziness"},{"rate":"3-5","effect":"Headache"},{"rate":"2-4","effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL1073","moleculeType":"Small molecule","molecularWeight":"445.55"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Glipizide is a second-generation sulfonylurea that binds to and closes ATP-sensitive potassium channels on the surface of pancreatic beta cells. This closure depolarizes the cell membrane, triggering calcium influx and subsequent insulin exocytosis. The increased circulating insulin reduces blood glucose levels in patients with type 2 diabetes mellitus.","oneSentence":"Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:41.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01698775","phase":"PHASE3","title":"A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-02","conditions":"Type 2 Diabetes Mellitus","enrollment":213},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00509262","phase":"PHASE3","title":"Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-09","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic","enrollment":426},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT00095056","phase":"PHASE3","title":"An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10","conditions":"Diabetes Mellitus, Type 2, Chronic Renal Insufficiency","enrollment":91},{"nctId":"NCT00707993","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Diabetes Mellitus","enrollment":441},{"nctId":"NCT01020123","phase":"PHASE2","title":"Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type II Diabetes Mellitus","enrollment":530},{"nctId":"NCT01068860","phase":"PHASE2","title":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus, Impaired Glucose Tolerance","enrollment":246}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":106,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to glipizide","genericName":"Placebo to glipizide","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}